$GMED Cashflow Statement | Understand Stock

$GMED

$80.90 -$0.93 (1.14%) Close

$GMED Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Bargain purchase gain
Acquired in-process research and development
Depreciation and amortization
Amortization of premiums on marketable securities
Provision for excess and obsolete inventory
Amortization of inventory fair value step up
Amortization of 2025 Notes fair value step up
Amortization of acquisition accounting fair value step-up
Stock-based compensation expense
Allowance for expected credit losses
Change in fair value of business acquisition liabilities
Change in deferred income taxes
(Gain)/loss on disposal of assets, net
Payment of business acquisition-related liabilities
Net (gain)/loss from foreign currency adjustment
(Increase) decrease in:
Accounts receivable
Inventories
Prepaid expenses and other assets
Increase (decrease) in:
Accounts payable
Accrued expenses and other liabilities
Income taxes payable/receivable
Net cash provided by/(used in) operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Sales of marketable securities
Purchases of property and equipment
Acquisition of businesses, net of cash acquired and purchases of intangible and other assets
Acquisition of intangible assets
Net cash provided by/(used in) investing activities
Cash flows from financing activities:
Payment of business acquisition-related liabilities
Net proceeds from exercise of stock options
Payments related to tax withholdings for share-based compensation
Repurchase of common stock
Repayment of senior convertible notes
Net cash provided by/(used in) financing activities
Effect of foreign exchange rates on cash
Net increase/(decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Income taxes paid, net
Non-cash investing and financing activities:
Equity issued in conjunction with the NuVasive Merger
Accrued purchases of property and equipment
Income taxes paid, net
Federal
State
Foreign
Australia
Other
Total foreign

Comments